Registry of Lobbyists

Registration - In-house Organization

Innovative Medicines Canada / Médicaments novateurs Canada / David Renwick, Interim President

Registration Information

In-house Organization name: Innovative Medicines Canada / Médicaments novateurs Canada
Previous in-house organization names
Responsible Officer Name: David Renwick, Interim President 
Responsible Officer Change History
Initial registration start date: 2004-08-19
Registration status: Active
Registration Number: 956428-371

Associated Communications

Total Number of Communication Reports: 912

Monthly communication reports in the last 6 months: 38

Version 1 of 108 (2004-08-19 to 2005-04-12)

Version 1 of 108 (2004-08-19 to 2005-04-12) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.

A. Organization Information

Organization: CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES (RX&D)
1220 - 55 METCALFE STREET
OTTAWA, ON  K1P 6L5
Canada
Telephone number: 613-236-0455
Fax number: 613-236-7919  
Responsible officer name and position during the period of this registration: RUSSELL WILLIAMS, PRESIDENT  
 
Description of the organization's activities: CANADA'S RESEARCH-BASED PHARMACEUTICAL INDUSTRY (RX&D) IS THE ASSOCIATION OF CANADA'S RESEARCH-BASED PHARMACEUTICAL INDUSTRY. THE COMPANIES THAT MAKE UP THE MEMBERSHIP OF RX&D ARE ENGAGED IN THE RESEARCH AND DEVELOPMENT, PRODUCTION, MARKETING, AND SERVICING OF PRESCRIPTION AND PROFESSIONAL NON-PRESCRIPTION PHARMACEUTICALS. RX&D MEMBERS EMPLOY MORE THAN 18,000 PEOPLE ACROSS CANADA. COMPRISED OF COMPANIES OF ALL SIZES, RX&D MEMBERSHIP REFLECTS THE INTERNATIONAL SCOPE OF TODAY'S MODERN PHARMACEUTICAL INDUSTRY AND INCLUDES THE CANADIAN OPERATIONS OF DOMESTIC FIRMS, AS WELL AS THOSE WITH HEADQUARTERS IN OTHER COUNTRIES. RX&D MEMBERSHIP IS CURRENTLY MADE UP OF 59 MEMBER COMPANIES.
Organization's membership or classes of membership: FULL MEMBERS - CORPORATE PARTNERSHIPS, FIRMS AND CORPORATIONS OR SUBSIDIARIES WHO RESEARCH, DEVELOP, MANUFACTURE AND/OR DISTRIBUTE BRAND NAME PHARMACEUTICALS. RESEARCH ASSOCIATE MEMBERS - CORPORATE PARTNERSHIPS, FIRMS AND CORPORATIONS OR SUBSIDIARIES WHO ARE ENGAGED FOR PROFIT IN RESEARCH AND DEVELOPMENT OF PHARMACEUTICAL PRODUCTS. MANUFACTURING AFFILIATE MEMBERSHIP - CORPORATE PARTNERSHIPS, FIRMS AND CORPORATIONS OR SUBSIDIARIES WHO ARE ENGAGED IN CUSTOM MANUFACTURING OR CUSTOM PACKAGING, FOR OR SUPPLY PHARMACEUTICAL CHEMICALS TO FULL MEMBERS.
 
Was the organization funded in whole or in part by any domestic or foreign government institution in the last completed financial year? No
 

B. Lobbyists Employed by the Organization

Name: MARC DESMARAIS
Position title: VICE-PRESIDENT, FEDERAL GOVERNMENT AFFAIRS
Public offices held: N/A. Disclosure of this information was not a requirement prior to June 20, 2005.
 
Name: MARIANNE GOODWIN
Position title: DIRECTRICE DES AFFIARES GOUVERNEMENTAL FEDERALE
Public offices held: N/A. Disclosure of this information was not a requirement prior to June 20, 2005.
 
Name: JULIE LATREMOUILLE
Position title: DIRECTOR, REGULATORY AFFAIRS
Public offices held: N/A. Disclosure of this information was not a requirement prior to June 20, 2005.
 
Name: JACQUES LEFEBVRE
Position title: VICE-PRESIDENT, COMMUNICATIONS AND PUBLIC AFFAIRS
Public offices held: N/A. Disclosure of this information was not a requirement prior to June 20, 2005.
 
Name: BENOIT VIOLETTE
Position title: SENIOR ADVISOR, FEDERAL GOV. AFFAIRS
Public offices held: N/A. Disclosure of this information was not a requirement prior to June 20, 2005.
 
Name: RUSSELL WILLIAMS
Position title: PRESIDENT
Public offices held: N/A. Disclosure of this information was not a requirement prior to June 20, 2005.
 

C. Lobbying Activity Information

Federal departments or organizations which have been or will be communicated with during the course of the undertaking: Atlantic Canada Opportunities Agency (ACOA), Environment Canada, Finance Canada (FIN), Foreign Affairs and International Trade Canada (DFAITC), Health Canada (HC), Industry Canada
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Informal communications, Meetings, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format
 
Subject Matter: Areas of Concern: Aboriginal Affairs, Agriculture, Arts and Culture, Broadcasting, Constitutional Issues, Consumer Issues, Defence, Education, Employment and Training, Energy, Environment, Financial Institutions, Fisheries, Forestry, Government Procurement, Health, Immigration, Industry, Infrastructure, Intellectual Property, Internal Trade, International Relations, International Trade, Justice and Law Enforcement, Labour, Mining, Regional Development, Science and Technology, Small Business, Sports, Taxation and Finance, Telecommunications, Tourism, Transportation
 
Subject Matter: Retrospective: IND. CDA - POLITICAL/BUREAUCRAT. BILL C-91(DRUG PATENT), NOC-PATENT LINKAGE REGULATIONSPMPRB - PATENTED MEDICINES PRICING AND R&D POLICY, PUBLIC CONSULTATIONS ON MANDATE REVENUE CANADA - BUDGET AND TAXATION ISSUES AFFECTING THE PHARMACEUTICAL INDUSTRY, SCIENTIFIC RESEARCH AND EXPERIMENTAL DEVELOPMENT (SR&ED)HEALTH CANADA - POLITICAL/BUREAU. COST RECOVERY, DRUG ADVERTISING, REGULATORY POLICIES, DRUG REVIEW TIMES INT'L TRADE - INTERNATIONAL AID PROGRAMS, WORLD HEALTH ORGANIZATION, WORLD TRADE ORGANIZATION HEALTH CANADA - KNOWLEDGE IS BEST MEDICINE CAMPAIGN TREASURY BOARD - COST RECOVERY INIATIVES ENVIR. CDA - ISSUES AFFECTING PHARMACEUTICALS REVENUE CDA - ISSUES AFFECTING SCIENTIFIC RESEARCH EXPENDITURES CANADIAN INSTITUES OF HEALTH RESEARCH - PARTNERSHIPS
Subject Matter: Prospective: INDUSTRY CANADA - INTELLECTUAL PROPERTY - PATENT REGULATIONS; WORLD TRADE ORGANIZATION, PHARMACEUTICAL R&D ISSUES (SR&ED)HEALTH CANADA - COST RECOVERY, DRUG ADVERTISING, KNOWLEDGE CAMPAIGN, INTERNATIONAL MRA'S (MUTUAL RECOGNITION AGREEMENTS - INTERNATIONAL RECOGNITION OF COUNTRY-TO-COUNTRY PLANT INSPECTIONS, DRUG APPROVALS, ETC.), DRUG APPROVAL PROCESS, CANADIAN INSITUTES OF HEALTH RESEARCH - ONGOING ISSUE WITH PARTNERSHIP; INT'L TRADE - ONGOING INTERNATIONAL ISSUES; WORLD TRADE ORGANIZATION, INTERNATIONAL PATENT ISSUESREVENUE CDA - BUDGET ITEMS, SRED (SCIENTIFIC RESEARCH AND EXPERIMENTAL DEVELOPMENT)TREASURY BD - COST RECOVERY, USER FEE POLICY;




Date Modified: